- Previous Close
0.0475 - Open
0.0488 - Bid 0.0440 x --
- Ask 0.0500 x --
- Day's Range
0.0440 - 0.0488 - 52 Week Range
0.0400 - 0.4400 - Volume
6,160,838 - Avg. Volume
16,329,009 - Market Cap (intraday)
681,269 - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date Dec 31, 2024 - Jan 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
www.nuformix.comRecent News: NFX.L
View MorePerformance Overview: NFX.L
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NFX.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NFX.L
View MoreValuation Measures
Market Cap
667.08k
Enterprise Value
483.55k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.16
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-477.88k
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
183.52k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--